Kenvue Inc. (KVUE)
| Market Cap | 31.36B |
| Revenue (ttm) | 15.14B |
| Net Income (ttm) | 1.42B |
| Shares Out | 1.92B |
| EPS (ttm) | 0.74 |
| PE Ratio | 22.08 |
| Forward PE | 15.25 |
| Dividend | $0.83 (5.08%) |
| Ex-Dividend Date | Aug 13, 2025 |
| Volume | 39,463,507 |
| Open | 16.50 |
| Previous Close | 16.42 |
| Day's Range | 16.13 - 16.60 |
| 52-Week Range | 16.07 - 25.17 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | 23.18 (+41.86%) |
| Earnings Date | Nov 6, 2025 |
About KVUE
Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other... [Read more]
Financial Performance
In 2024, Kenvue's revenue was $15.46 billion, an increase of 0.07% compared to the previous year's $15.44 billion. Earnings were $1.03 billion, a decrease of -38.10%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for KVUE stock is "Buy." The 12-month stock price target is $23.18, which is an increase of 41.86% from the latest price.
News
Kenvue: Trump-Era Volatility Presents A More Attractive Opportunity, But Headwinds Remain
Kenvue faces near-term headwinds from Tylenol-autism allegations, macro uncertainty, and segment underperformance, but offers long-term income potential. Recent leadership changes and a focus on core ...
The CEO behind Tylenol thought he'd found a way to work with the Trump administration. Then everything went off the rails.
The CEO behind Tylenol thought he'd found a way to work with the Trump administration. Then everything went off the rails.
Trump repeats Tylenol and vaccine claims, defying medical community outcry
U.S. President Donald Trump on Friday repeated his call for pregnant women and young children to stop using popular pain medication Tylenol, defying widespread criticism from medical groups, and offer...
51 September S&P Hi-Yield Aristocrats: 5 To Buy
The article highlights the top ten S&P Hi-Yield Aristocrats for September, with nine stocks offering attractive yields and fair pricing for dividend investors. Analyst forecasts project potential net ...
RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next?
Tylenol may be only the beginning.
Attorneys urge court overseeing Tylenol autism lawsuits to consider Trump administration's stance
Families appealing the dismissal of their lawsuits alleging that Kenvue's Tylenol or generic versions of the pain-relief medication caused their children's autism are asking an appeals court to consid...
RFK Jr.'s team wanted to tout an autism therapy. But a meeting with Tylenol's maker convinced the U.S. health secretary to put the emphasis on acetaminophen
The heads of key health agencies advocated for putting the emphasis on leucovorin, but Kennedy became convinced that he had a moral duty to get the word out about the risk of acetaminophen.
Kenvue: This Too Shall Pass
Kenvue shares have dropped 17% following reports linking Tylenol to autism, creating a potential long-term buying opportunity. The market reaction appears to be an overreaction, as Tylenol accounts fo...
Trump links autism to Tylenol ingredient use during pregnancy — here's what to know
The Trump administration on Monday drew an unproven link between autism and pregnant women's use of acetaminophen, the active ingredient in one of the world's most common over-the-counter pain relieve...
Tylenol maker Kenvue rebounds after Trump spreads unproven claims
Shares of Tylenol maker Kenvue bounced back sharply at the opening bell Tuesday, a day after President Donald Trump promoted unproven and, in some cases, discredited ties between Tylenol, vaccines, an...
Kenvue Stock Recoups Losses After Trump Links Tylenol to Autism
Kenvue stock is rebounding. It may be a largely a case of things-could've-been- worse.
How Trump is spreading unproven information about Tylenol, autism, and vaccines
President Donald Trump on Monday used the platform of the presidency to promote unproven and in some cases discredited ties between Tylenol, vaccines and autism as his administration announced a wide-...
Tylenol: Kenvue's Sobering Reality
I'm initiating Kenvue Inc. with a Buy after a sharp selloff following President Donald Trump's remarks on Monday linking Tylenol with autism. KVUE's profitability, with gross margins above 58% and EBI...
Global reaction to Trump's unproven claim about Tylenol's link to autism
U.S. President Donald Trump on Monday linked autism to childhood vaccines and the use of popular pain medication Tylenol by women when pregnant, elevating claims not backed by scientific evidence to t...
Shares of Kenvue rebound today after Trump admin ties use of acetaminophen to autism
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on the Trump administration's announcement linking acetaminophen taken during pregnancy to autism.
KVUE Rebounds Against Trump Admin, BA International Boost, AZO Earnings Miss
Kenvue (KVUE) rallied Tuesday morning despite the Trump administration linking Tylenol to autism. Diane King Hall notes that analyst commentary may have helped the stock's upward trajectory.
Tylenol Maker Kenvue Shares Rebound After Trump Links Drug To Autism
23%. That's the estimated percentage of adults in the U.S.—roughly 52 million people—who consume a medicine with acetaminophen each week, according to the nonprofit Consumer Healthcare Products Associ...
Tylenol Maker Kenvue Rebounds In Premarket After Trump Links Drug To Autism
23%. That's the estimated percentage of adults in the U.S.—roughly 52 million people—who consume a medicine with acetaminophen each week, according to the nonprofit Consumer Healthcare Products Associ...
Trump admin draws unproven link between autism and Tylenol ingredient use during pregnancy.
The Trump administration on Monday drew an unproven link between autism and pregnant women's use of acetaminophen, the active ingredient in one of the world's most common over-the-counter pain relieve...
Kenvue rebounds after Trump Tylenol claims as analysts see limited legal risk
Kenvue shares rose more than 5% in premarket trading on Tuesday, staging a recovery from a record low hit the previous session after US President Donald Trump linked the company's popular pain relieve...
Kenvue Stock Bounces Back After Trump Links Tylenol to Autism. Here's Why.
“Independent, sound science clearly shows that taking acetaminophen does not cause autism,” a Kenvue spokesperson told Barron's.
Trump Sounds The Alarm On Tylenol
The Trump administration has warned that the use of Tylenol during pregnancy might be linked to autism in children, a claim that is not backed by scientific evidence. Trump officials also claimed that...
Wall Street Breakfast Podcast: Kenvue In Focus
Kenvue (KVUE) rebounds 6% premarket after sharp drop, following FDA warning on acetaminophen use during pregnancy and company defense of Tylenol's safety. Boeing (BA) secures Uzbekistan Airways' large...
Kenvue stock rallies off record low after Trump press conference on alleged Tylenol-autism link
Kenvue stock rallied on Tuesday off a record low, after a White House press conference didn't offer fresh evidence that could be used by plaintiffs to sue the maker of Tylenol for its alleged link to ...
Tylenol-maker Kenvue shares bounce, Trump claims face pushback
Tylenol-maker Kenvue stock rose in European trading on Tuesday, even after U.S. President Donald Trump linked its popular pain medication to autism risk during pregnancy.